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INTRODUCTION:  Huge  hepatocellular  carcinoma  (HCC)  possesses  a potential  risk  for spontaneous  rupture,
which leads  to a life-threatening  complication  with  a high  mortality  rate.  In addition,  a large  HCC  is
frequently  accompanied  by  intrahepatic  metastases.
PRESENTATION  OF  CASE:  We  describe,  the  case  of  a 74-year-old  woman  with  a huge  extrahepatically
expanding  HCC  with  multiple  intrahepatic  metastases  who  was  treated  by  liver  resection  with  repeated
transcatheter  arterial  chemoembolization  (TACE).  To  prevent  tumor  rupture  or bleeding,  we  performed
right hepatectomy.  After  the operation,  TACE  was applied  for multiple  intrahepatic  metastases  in  the  rem-
nant liver.  Furthermore,  the  elevated  protein  induced  vitamin  K  absence  (PIVKA  II)  level  had  decreased
to  limits  within  the  normal  range.  Three  months  after  the ﬁrst  TACE,  computed  tomography  revealed
several  recurrences  in  the  liver.  TACE  was  applied  for the second  and  third  time  and  the  tumors  were
well  controlled.
DISCUSSION:  Although,  liver  resection  is  occasionally  performed  for patients  with  huge  HCC  to  avoid
spontaneous  tumor  rupture,  only surgical  approach  might  not  be sufﬁcient  for such  advanced  HCC. To
achieve long-term  survival,  it is necessary  to control  the  residual  intrahepatic  tumors.  We  could  control
multiple  intrahepatic  metastases  with  repeated  TACEs  after  hepatectomy.
CONCLUSION:  Multimodal  treatment  involving  hepatectomy  and  TACE  might  be a good  treatment  strategy
for  patients  with  huge  HCC  with  multiple  intrahepatic  metastases  if the tumors  are  localized  in  the  liver
without  distant  or peritoneal  metastasis.
© 2015  The  Authors.  Published  by  Elsevier  Ltd.  on behalf  of IJS  Publishing  Group  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction
Hepatocellular carcinoma (HCC) is one of the most common
alignancies and the third leading cause of cancer-related death
orldwide [1–3]. Surgical resection has been established as a stan-
ard treatment for HCC with the postoperative mortality rates of
–6.4% and 5-year survival rates of 39–50% [1,2,4,5]. Although,
ecent advances in imaging modalities have enabled an early detec-
ion of HCC, some patients still present with a large HCC (i.e.,
10 cm). A large tumor diameter and extrahepatically expanding
rowth pattern are associated with spontaneous tumor rupture
f HCC [6,7]. To prevent tumor rupture, hepatectomy should be
erformed if liver function is maintained. Although, unfavorable,
isease-free, and overall survival rates following surgical resection
or large HCC may  lead to the contraindication of surgical treat-
ent, several studies have reported the efﬁcacy and safety of liver
esection for large HCC [8–10].
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Large HCC is frequently accompanied by multiple intrahep-
atic metastases. Several authors have reported the effectiveness
of hepatectomy for main tumor in combination with transcatheter
arterial chemoembolization (TACE) [11–13]. Here we  describe, the
case of a multimodal treatment, including liver resection and TACE
for a patient with a huge HCC (30 cm)  with multiple intrahepatic
metastases to aim for preventing tumor rupture and leading to the
patient’s long-time survival.
2. Case report
2.1. Preoperative evaluation of the patient
A 74-year-old woman who complained of bilateral leg edema
was admitted to a nearby hospital. The patient’s medical history
was unremarkable, and she did not drink alcohol. She was  nega-
tive for hepatitis B surface antigen (HBsAg), positive for anti-HBs
antibody, and negative for anti-hepatitis C antibody. The patient’s
serum albumin level was  3.8 mg/dl, T-bil level was  0.8 mg/dl,
prothrombin time percentage was  127%, and indocyanine green
retention rate at 15 min  (ICGR15) was 12%. The comprehensive
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Contrast CT scan of the abdomen. (A) The CT scan of the abdomen showing a
27-cm huge tumor with extrahepatic expanding growth from the right lobe of the
liver to the pelvic cavity. The posterior branch of the right hepatic artery is shown by
arrows. Slight ascites was detected in the pelvic cavity. (A, B) There were multiple
intrahepatic metastases in the left lobe (arrow head).
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Fig. 2. A huge tumor occupied the entire right side of the abdominal cavity from
the  liver to the pelvic space. Slight ascites but no peritoneal metastasis was  found
in  the abdominal cavity.iver function was classiﬁed as Child’s A. Regarding biochemical
nalysis, alpha fetoprotein (AFP) and protein induced vitamin K
bsence (PIVKA II) levels were markedly elevated to 21.4 ng/ml
nd 108,518 MAU/ml, respectively. Computed tomography (CT)
evealed a huge extrahepatically expanding HCC originating from
he posterior segment of the liver to the pelvic cavity, which was
7 cm in length (Fig. 1A and B). In addition, there were multiple
ntrahepatic metastases in the left lobe. No peritoneal or extrahep-
tic metastasis was detected by CT or magnetic resonance imaging.
reoperative CT volumetry using Synapse Vincent® (Fujiﬁlm Medi-
al Co., Ltd., Tokyo, Japan) imaging software revealed a liver volume
f 2678 ml,  tumor volume of 1792 ml,  functional liver volume of
86 ml,  and estimated total liver volume of 1019 ml.  Moreover, this
nalysis indicated that if right hepatectomy could be performed, the
uture remnant liver volume would be 652 ml  (64% of the estimated
otal liver volume).2.2. Operation
A huge HCC was  found occupying the right side of the abdom-
inal cavity from the liver to the pelvic cavity (Fig. 2). Slight ascites
but no peritoneal metastasis was found in the abdominal cavity.
Multiple extrahepatic collateral vessels from surrounding tissue
such as the great omentum were observed. However, the tumor
did not invade other organs such as the transverse colon, small
intestine, diaphragm, or retroperitoneum. First, the tumor was
dissected from the great omentum. Although careful attention
was paid to avoid tumor rupture, oozing hemorrhage from the
tumor surface continued and was controlled by the application of
VIO soft-coagulation system (EREB Elecromedizin GmbH, Tuebin-
gen, Germany) with an IO electrodeTM (AMCO Inc., Tokyo, Japan)
or a ﬁbrin sealant patch (TachoSil®, Takeda, Osaka, Japan). After
cholecystectomy, the right hepatic artery and the right portal
vein were ligated and divided. Then, bleeding from the tumor
surface remarkably decreased. Although, the complete mobiliza-
tion of the right liver before parenchymal transection could not
be achieved due to the huge size of the tumor, we  applied the
liver hanging maneuver. Liver transection was accomplished with
a regular Péan clamp-crushing technique and harmonic scalpel
(Ethicon Endo-Surgery, Inc., Cincinnati, OH). The hemostasis of
the cut surface of the liver was achieved by ligation and the
application of TachoSil®. Two  abdominal drains were left in
place.
The operative time was  309 min, and the estimated blood loss
was 2825 ml  with intraoperative transfusion. The resected liver vol-
ume was 3230 g and the tumor size was 30 × 20 × 9 cm (Fig. 3).
Pathological examination revealed that the tumor consisted of well
and moderately differentiated and some poorly differentiated HCC;
the tumor margin was  negative. According to the 7th edition of the
UICC TNM staging system for HCC, this case was classiﬁed as pT3a
pN0 pM0, Stage IIIA.
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Fig. 3. The volume of the resected liver was 3230 g, and the size of the resected
tumor was 30 × 20 × 9 cm.
Fig. 4. The levels of PIVKA II during the postoperative course. After operation and
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invasion to other organ is rare. Therefore, liver resection couldhe  ﬁrst administration of TACE, the levels of PIVKA II decreased to limits within the
ormal range.
.3. Postoperative course
The patient developed a postoperative superﬁcial surgical site
nfection, intra-abdominal abscess, and pleural effusion. She was
reated with a percutaneous drainage and antibiotics. On postop-
rative day 60, TACE was performed to treat multiple HCCs in the
emnant liver. After this multimodal therapy, the AFP and PIVKA-II
evels decreased to limits within the normal range (Fig. 4).
One month after TACE, no new lesion was found on CT. Five
onths after the hepatectomy, multiple intrahepatic recurrences
ere detected. A second TACE was performed for the recurrent
umors. Three months after the second TACE, a third TACE was
pplied for recurrent tumors. One month after the third TACE, she
eveloped pneumonia and recovered upon treatment with antibi-
tics. Because of her worsening performance status, TACE could not
e applied again. Six months after the withdrawal of TACE her liverPEN  ACCESS
rgery Case Reports 16 (2015) 44–47
function gradually worsened and she died of liver failure 18 months
after hepatectomy.
3. Discussion
In the present report, despite the presence of a huge HCC with
multiple intrahepatic metastases, the patient was able to achieve
an acceptable survival of 18 months through an aggressive mul-
timodal therapy combining hepatectomy for the main tumor and
repeated TACE for intrahepatic metastases in the remnant liver. To
the best of our knowledge, this case was the largest HCC that had
been previously reported.
Despite the recent improvements in imaging modalities such
as multi detector row CT or contrast-enhanced magnetic reso-
nance imaging, some patients still present with advanced-staged
HCC with a large primary tumor accompanied by multiple intra-
hepatic metastases. However, there has been no widely accepted
consensus regarding the treatment of such advanced cases of HCC.
A large tumor diameter and extrahepatically expanding growth
pattern are risk factors for the tumor rupture of HCC [6,7], which
is a life-threatening complication with a high mortality rate [14].
Recent publications have reported that the incidence of sponta-
neous tumor rupture range from 3% to 26% among patients with
HCCs, and their corresponding mortality rates are notably high (25%
to 100%) [15,16]. In this setting, TACE should not be considered
because of its poor prognosis for large HCC. Several authors have
reported an unfavorable 5-year survival rate of 5.0–7.2% in patients
who underwent TACE for HCC larger than 5 cm [17,18]. In contrast,
recent publications have reported acceptable long-term outcomes
with 5-year survival rates ranging from 24.5% to 33% for patients
who underwent hepatectomy for large HCC [8–10]. Although, these
reports described retrospective studies, liver resection seems to be
the only way  to achieve long-term survival in cases of large HCC.
Therefore, liver resection may  be justiﬁed for patients with huge
HCC to avoid spontaneous tumor rupture and to achieve long-term
survival. In the present report, the patient had an extrahepatically
expanding large HCC with a diameter of 30 cm,  which totally occu-
pied the right side of the abdominal cavity. It seemed that tumor
rupture may  occur soon, which would lead to major bleeding and
death.
On the other hand, a large HCC is frequently accompanied by
intrahepatic metastases. A surgical approach alone may  not be suf-
ﬁcient for such advanced HCC, and it is necessary to control the
residual intrahepatic tumors to achieve long-term survival. Sev-
eral authors have reported the effectiveness of reduction surgery
in combination with TACE for large HCC with multiple intrahep-
atic metastases [11–13]. Despite the lack of clear evidence in the
treatment for such advanced HCC, multimodal treatment combin-
ing liver resection and TACE might be a good treatment strategy
to achieve favorable long-term outcomes. Although our case was
a far advanced HCC presenting a huge nodule of 30 cm in diam-
eter with multiple metastases, the tumors were localized only in
the liver without their invasion in the other organs or extrahepatic
metastases during the treatment period.
We  reported a case of advanced HCC with a huge primary
tumor and multiple intrahepatic metastases. For the treatment of
such patients, surgeons should keep in mind that it is necessary
to prevent severe tumor rupture, which can be achieved by liver
resection. Even though, the tumor is huge and extrahepatically
expanding such as our case, majority of HCC has capsule and directbe achieved safely in selected patients when sufﬁcient remnant
liver volume was  preserved. Multimodal treatment involving hep-
atectomy and TACE might be a good treatment strategy for these
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atients if the tumors are localized in liver with no distant or peri-
oneal metastasis.
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